101 Therapeutics develops novel platforms utilizing targeted molecular therapies to address inflammatory disorders. Their technology aims to reduce the severity and frequency of symptoms associated with these conditions, improving patient quality of life.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Inflammatory disorders often require broad immunosuppressant drugs that can cause systemic side effects and fail to precisely target the underlying disease mechanisms. This can lead to suboptimal treatment outcomes and reduced quality of life for patients.
Solution
101 Therapeutics is developing targeted molecular therapies designed to address inflammatory disorders with greater precision and fewer systemic side effects. Their platform aims to selectively modulate key signaling pathways involved in inflammation, offering a more focused approach to treatment. By targeting the root causes of inflammation at the molecular level, 101 Therapeutics seeks to reduce the severity and frequency of symptoms, ultimately improving patient outcomes and quality of life.
Target Audience
The primary target audience includes patients suffering from inflammatory disorders and healthcare providers seeking more targeted and effective treatment options.
Features
- Targeted molecular therapies for inflammatory disorders
- Selective modulation of key signaling pathways
- Reduced systemic side effects compared to broad immunosuppressants